{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":60,"searchCount":0},"additional":{"submitter":["Chen B"],"funding":["National Institute of General Medical Sciences of the National Institutes of Health","NIGMS NIH HHS"],"pagination":["285-97"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4785018"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["99(3)"],"pubmed_abstract":["The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine."],"journal":["Clinical pharmacology and therapeutics"],"pubmed_title":["Leveraging big data to transform target selection and drug discovery."],"pmcid":["PMC4785018"],"funding_grant_id":["R01 GM079719","R01GM079719"],"pubmed_authors":["Chen B","Butte AJ"],"view_count":["60"],"additional_accession":[]},"is_claimable":false,"name":"Leveraging big data to transform target selection and drug discovery.","description":"The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2024-11-21T05:30:59.857Z","creation":"2019-03-27T02:10:45Z"},"accession":"S-EPMC4785018","cross_references":{"pubmed":["26659699"],"doi":["10.1002/cpt.318"]}}